Informed consent in clinical trials using stem cells: Suggestions and points of attention from informed consent training workshops in Japan by Kusunose, M et al.
August 2015, Vol. 8, No. 2, Supplement 1    SAJBL     49
INFORMED CONSENT
The world’s first-in-human (FIH) clinical trial using 
induced pluripotent stem cells (iPSCs) was conducted 
in Japan in 2014.[1,2] Stem cell clinical trials have raised 
concerns over a variety of ethical issues including: how 
well prospective research participants (PRPs) have been informed 
about the nature of the trials, patients’ therapeutic misconceptions 
about the trials, and the need for long-term safety observations of trial 
participants. These and other scientific issues associated with iPSCs 
distinguish research in regenerative medicine from ordinary research 
on therapeutic developments and have led to questions on how well 
the typical informed consent (IC) process works for these trials.
 Informed consent is an essential requirement of ethical research 
involving human participants, and contains three key components: 
information, comprehension, and voluntariness.[3] Usually IC is 
achieved by providing PRPs with a document that explains the 
study and its procedures. However, transplanted cells differentiated 
from iPSCs as they were genetically manipulated and long-term 
observation of trial participants is mandatory for early detection 
of unknown side effects. We need to put greater emphasis on 
informing participants about the nature of the trial and the  potential 
after-effects. Informed consent documents cannot always anticipate 
all participant informational needs, increasing the importance of 
question and answer sessions between PRPs and those responsible 
for obtaining full IC. 
One way to address IC incompleteness is establishing standards for 
IC documents and procedures. Several organisations have suggested 
standards and guidelines for more fully informing PRPs in order to 
ensure a clear understanding of IC associated with stem cell research. 
The International Society for Stem Cell Research (ISSCR) propose the 
following guidelines:
•  Patients need to be informed when stem cell-derived products 
have never been tested before in humans and if researchers do not 
know whether they will work as hoped.
• Cell-based interventions, unlike many pharmacological products or 
even many implantable medical devices, may not leave the body 
and may continue to generate adverse effects for the lifetime of the 
patient. The possible irreversibility of a cellular transplant should 
be explained clearly. 
• Subjects should be informed about the source of the cells so that 
their values are respected.
• Ensuring subject comprehension must be done at each phase of 
the clinical trials process. Ideally, the subject’s comprehension of 
information should be assessed through a written test or an oral 
quiz during the time of obtaining consent. 
• Human subjects’ research committees should ensure that informed 
consent documents accurately portray these uncertainties and 
potential risks, and clearly explain the experimental nature of the 
clinical study.[4]
Aalto-Setälä et al [5] suggest guidelines that permit PRPs’ participation 
in stem cell research only if they agree to specific conditions: genetic 
modification of cells; injection of iPSCs or their derivations into non-
human animals, including injections into the brain; sharing cell lines 
with other researchers with appropriate confidentiality protection; 
and patenting scientific discoveries and developing commercial tests 
and therapies, with no sharing of royalties with cell donors. 
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Informed consent (IC) is an essential requirement of ethical research involving human participants, and is usually achieved by providing 
prospective research participants (PRPs) with a document that explains the study and its procedures. However, results of a series of IC 
workshops held in Tokyo during 2014 indicate that consent forms alone are not enough to achieve full IC in regenerative medicine research, 
due to the necessity of long-term patient-safety observations to meet the ethical challenges of such research. Adequate training of the 
people who are responsible for obtaining IC (elucidators) is also necessary to ensure full IC. Elucidators must be able to provide PRPs with 
sufficient information to ensure adequate comprehension of the study and its potential after-effects; judge PRPs’ voluntariness and eligibility; 
and establish and/or maintain partnerships with PRPs. The workshops used role-playing simulations, to demonstrate how to effectively 
obtain fuller IC, to members of several Japanese research groups preparing for clinical stem cell trials. Workshop results were correlated with 
the results of a 2013 workshop on what information patients want when considering participation in induced pluripotent stem cell (iPSC) 
research. The correlated results showed the need for continuous training and education of elucidators in order to make sure that they acquire 
and maintain IC competency. 
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Each recommendation brings different ethical concerns to any 
discussion about IC reforms. The many ethical problems revealed 
in the recommendations show that improving IC related to stem 
cell research is a pressing issue that needs to be resolved to protect 
research participants.
Purpose
This paper examines the results of a series of workshops conducted 
in 2014 to determine specific areas of concern regarding IC and to 
identify methods to address these concerns. Workshop results are 
then compared to a 2013 workshop that studied what information 
is wanted by patients when considering participation in iPSC 
research. Each study was concerned with different aspects of the role 
elucidators play in achieving full IC. For the purpose of this paper, we 
have defined ‘elucidators’ as ‘people who obtain and are in charge of 
IC’, even though IC is usually conducted by investigators, physicians, 
research nurses, or clinical research coordinators.
Method
Workshops on IC in clinical trials using stem cells were conducted 
in Tokyo in February and November 2014. We accepted applications 
for the workshops from Japanese research groups enrolled in the 
‘Highway Program for the Realization of Regenerative Medicine’, 
funded by the Japan Science and Technology Agency, who planned 
to conduct stem cell clinical trials in the near future. All participants 
conduct or support the IC process for PRPs or prepare consent forms 
for their research groups.
Prof. Sean Philpott-Jones, Director of the Bioethics Program/
Director of the Research Ethics Program for the Bioethics Program 
at Union Graduate College – Icahn School of Medicine at Mount 
Sinai in New York, was invited to lead the workshop. Prof. Philpott-
Jones has extensive experience with IC education using role-play 
methods. As part of the workshop preparation process, consent 
forms were carefully drafted to incorporate comprehensive 
information related to IC (Table 1) and the forms were distributed 
to the workshop participants (WPs) a week before the workshop 
began.
The February workshop served as a pilot study to obtain feedback 
from participants regarding workshop forms and procedures. Seven 
people participated in the four-and-a-half hour workshop. One male 
and one female from a group of volunteers, helping medical students 
prepare for the Objective Structured Clinical Examination (OSCE), 
acted as patients. WPs acted as IC elucidators. Two consent forms 
were prepared for the workshop: ‘Transplant of Chondrocytes Derived 
from Autologous Bone Marrow Mesenchymal Stem Cells (MSCs) for 
Cartilage Damage in Knee Joints (Phase I Trial)’ (educational material) 
and ‘Clinical Research on Autologous iPS Cell-Derived Retinal Pigment 
Epithelium Sheet Transplantation for Exudative Age-Related Macular 
Degeneration’ (a real consent form from the clinical trial). 
Feedback, following the pilot workshop, led to the creation of 
a new IC form for the ‘Transplant of Chondrocytes’ and to the 
recruitment of better performers as workshop patients.
In November, six people participated in a six-hour workshop. Two 
of the six had participated in the first workshop. For this workshop 
two female actors from an entertainment agency played the patients. 
As part of using the new IC form, bogus patient information and 
referrals were created to preserve confidentiality.
Both workshops used role-playing to teach how to obtain IC from PRPs. 
Volunteers and/or actors played patients. Characteristics, background, 
and medical conditions of the ‘patients’ were created in detail before-
hand so that the translational-research physician could play their parts 
realistically. In the workshop held in November (the MSC case), one actor 
played a woman whose husband had told her to participate in the trial 
so that she could get better and do more housework (Fig. 1). In the iPSC 
case, an actor played a young actor who did not want surgical scars on 
her body because of her occupation and was also struggling financially, 
which made her eager to try clinical trials; the character also wished to 
have a baby in the near future (Fig. 2). Both actors were required to ask 
specific questions, such as could they participate if pregnant, and were 
encouraged to ask for explanations for any jargon used during the 
session. They were also free to ask questions about anything else that 
they believed would help them decide whether to participate (except for 
specific medical issues that the clinical trials were not designed to treat).
Table 1. Drafting consent forms
• Introduction
• What is a clinical trial?
• Cartilage damage in knee
• Treatment of the knee joint
• About this clinical trial and its objective
• Methods of the clinical trial
• Selection criteria for research participants of this clinical trial




• Treatments other than this clinical trial
• Treatments after completion of this clinical trial
• Benefits
• Disadvantages
• Expense for participation in this clinical trial
• Treatment and coverage for health hazards caused by this clinical trial
• Privacy protection
• When we obtain new information on this clinical trial
• Consent for participation in this clinical trial
• Right of consent withdrawal
• Discontinuation of this clinical trial
• Specimen storage for safety check
• Access to records
• Intellectual property right
• Conflict of interest
• Funding sources of this clinical trial
• Contact information and consultation service
• Complaints counter
• Clinical research coordinators
• Address of discontinuation request
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11/07/2014
Dear Professor Taro Bando,
I would like to discuss one of our patients, Ms. xxxx. Though she has 
been treated at our hospital as an outpatient due to cartilage damage 
in her knee joints, she has also received conservative medical therapy 
as described below. However, she is now in thinking of surgical 
therapy due to disabling symptoms and other occupational reasons. 
Alternative therapies are autologous transplantation (‘mosaicplasty’), 
in which a part of the non-damaged knee cartilage is obtained 
and transplanted into the damaged area in order to facilitate the 
regeneration of hyaline cartilage; the use of autologous cultured 
cartilage called JACC which has been approved as regenerative 
medicine; and artificial joint replacement. I have also suggested 
transplantation of chondrocytes derived from autologous bone 
marrow mesenchymal stem cell for cartilage damage in knee joint.
When I told her about the research that was done with the second 
research subject, she told me she would like to hear about your 
clinical trial. I gave her a brief explanation but did not hand her a 
copy of the consent form. I would appreciate it if you could inform 
her about the clinical trial.
Patient information
Name: xxxxxxxx, Age 46 y/o, ID # xxxxxxxxx
Contact information: Address: xxxxxx Phone: # xxxxxx
Occupation: Tea ceremony instructor (runs a tea ceremony school at 
home)
Family history: Husband (physician), son, daughter, no special 
instructions
Anamnesis: No special instructions
Progress
Six months ago, when walking, she was knocked down and injured 
by a motorcycle driver. Bruise and torsion caused by the fall led to 
three days of hospitalization, during which the affected area was 
immobilized and kept under observation. Currently, she is under 
treatment for tibial cartilage damage as an outpatient.
For cartilage damage, the following are conducted: internal use of 
anti-inflammatory analgesic, intra-articular administration of steroid 
and hyaluronan once a week, and drainage of joint fluid when 
needed. Tumentia is slight; however, she complains of severe pains 
whenever she has to move about. 
Special instructions
She is a tea ceremony instructor and is eager to continue managing 
her tea ceremony school. However, she cannot go down on her 
knees due to the limitations in her knee range motion, and so she 
is face with the prospect of closing her business. Therefore, she 
wants therapy so that she can continue to work as an instructor 
at her tea ceremony school. Her husband is a physician. It seems 
that he is positively reinforcing her participation in the clinical trial 
and expecting her early recovery. She, on the other hand, has a 
propensity for anxiety, and she appears to have a fear of invasive 
therapy such as removal of autologous cartilage.
Professor Kazuo Ohmori, MD
Orthopaedist
Fig. 1. Patient information sheet – patient 1
11/07/2014
Dear Professor Bando,
I would like to introduce a patient, Ms. xxxx . She is in outpatient treatment 
at our hospital for cartilage damage in the keen joint, sustained in a 
traffic accident. Thus far, she has received conservative medical therapy; 
however, due to her disabling symptoms, I suggested to her that at this 
stage she might consider seeking surgical therapy. I explained a number 
of potential therapies, as follows: 1) anaplasty of the damaged area 
using an arthroscope (reducing physical stimuli by removing processus), 
2) drilling or microfracture (methods of bone marrow stimulation, 
which arthroscopically resect the subchondral bone), 3) mosaicplasty 
(autologous transplantation of knee cartilage), 4) autologous cultured car-
ti lage called JACC which is a medical product for regenerative medicine 
and 5) artificial joint replacement. My recommendation was that the final 
option, artificial joint replacement, is the most realistic; options 1-4 would 
not offer a comprehensive remedy, due to the large size of the damaged 
area. However, Ms. xxxx is still young. If she opts for artificial joint replace-
ment, she will require several additional replacement surgeries in the 
future, which will result in large scars. Additionally, bone malformation 
caused by the artificial joint will cause surgical difficulties to increase 
with each operation. Ms. xxxx is an active professional actor, and as such 
wants to keep scarring to a minimum. She is interested in treatment via 
chondrocytes derived from autologous iPS cells, a procedure she heard of 
through the press. She has stated that she would like to learn more about 
your clinical trial. I have explained the trial broadly, but have not given her 
a copy of the consent form. Treatment options 3 and 4 will be difficult to 
conduct because of the extent of the damaged area; however, I assume 
that it is possible to secure the necessary cell numbers if regenerative 
therapy with using iPS cells. I have also explained to her that there is no 
one who received this method. I thank you in advance for your support.
Patient information
Name: xxxxxx  Age: 29 y/o  ID #: xxxxxx
Contact address: xxxxxx  Contact phone #: xxxxxx
Occupation: Actor
Family history: Single / no special instructions
Anamnesis: No special instructions
Progress
Three months ago, the patient collided with a vehicle while bicycling. 
She was hospitalised at our facility to immobilise the affected area, 
and received follow-up care for two weeks. Currently, she is under 
treatment as an outpatient.
In the outpatient department, the following therapies are conducted: 
administration of internal anti-inflammatory analgesics; once weekly 
trial implementation of intra-articular steroid and hyaluronan 
administration; and drainage of joint fluid as needed. Tumentia is 
slight, but she complains of severe pain, particularly in movement, 
which interferes with her daily life.
Special instructions
Regarding her therapy, she does not want to be left with visible scars 
on account of her occupation. Currently she has no choice but to 
suspend her work as an actor, which causes her financial concern; she 
wants to return to her business as soon as possible. Although thus 
far she has focused on her profession, she has a boyfriend and is now 
considering future pregnancy. When I discussed your clinical trial with 
her, she had a positive outlook.
Professor Kazuo Ohmori, MD
Orthopaedist
Fig. 2. Patient information sheet – patient 2
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The workshops began with a lecture detailing six points important 
for IC: situation, perception, information, knowledge, empathy, 
and solutions (Table 2).[6] Then mock research protocols were 
introduced, followed by patients information, and a question-
and-answer session. The WPs then explained the research to 
each mock patient as part of comprehensive IC. The lectures and 
WPs’ performances were videotaped, and used to review their 
performances.
Workshop results were then compared to the results obtained in a 
2013 iPSC workshop conducted by the Japanese Retinitis Pigmentosa 
Society (JRPS) that featured a dialogue between retinitis pigmentosa 
patients and researchers. Correlating workshop results enabled both 
WP and PRP perspectives to be incorporated into recommendations 
for improving IC related to stem cell research.
Results
WP performance in the workshops
Although WPs performed well overall, they had difficulty with four of 
the six points deemed necessary for full IC: perception, information, 
knowledge, and empathy. 
Observations regarding WP performance
• WPs tended to take too much time explaining what they believed 
to be important or familiar, such as medical conditions and risks. 
• WPs provided the information requested on the consent form, but 
did so in a scattered order, based on the patients’ questions. 
• WPs paused sessions to get answers from the translational-
research physician for questions they could not anwer, such as 
medical procedures. The WPs then tried to explain the information 
to PRPs. 
• WPs who lacked IC training in the research context found it 
particularly difficult to explain research processes without using 
jargon. 
• Some WPs failed to notice non-verbal signs such as facial expressions 
or body language as indications of a patient’s understanding or 
concerns. For instance, in the case of the woman pressured by her 
husband, one WP neglected to suggest to the patient that it should 
be her decision to participate in the trial.
• Some WPs covered information too fast for the PRPs to follow 
because they focused too much on ‘explaining.’
Suggestions for improving WP performance
• If an elucidator takes too long to explain important aspects of a 
study it may imply bias regarding the PRP’s ability to participate in 
the study. For instance, if the elucidator highlights benefits or risk 
excessively, a PRP might think the elucidator is implying that he or 
she should or should not participate in the research. Manipulation, 
coercion, and misrepresentation should be avoided during IC. 
When explaining the research to PRPs, an elucidator should 
be careful not to misrepresent the research by overestimating 
benefits and underestimating risks. Even the order in which items 
are explained could affect a PRP’s decision. The elucidator should 
provide information in a neutral manner so that PRPs can make 
decisions based on their own thoughts and values.
• A well-written consent form should be a ‘roadmap’ ensuring all of 
the necessary elements are explained during IC. Elucidators should 
follow the order of the items listed on the consent form. It is during 
the icebreaking stage that: elucidators can ask PRPs about their 
reasons for participating in the research; their expectations and 
concerns; and allow the PRPs to ask questions and express their 
thoughts and feelings. Elucidators should always organise the 
meetings in ways that ensure  all important information is conveyed.
• WPs tended to think they had to answer every question that 
the PRPs asked. Some tried to provide medical explanations, 
which should be left to attending doctors to do. Elucidators 
should admit their lack of knowledge when asked a question 
beyond their expertise. The elucidator’s duty is not to provide 
information he or she is unfamiliar with but to advise PRPs to seek 
medical information or ask medical doctors for options before 
deciding to take part in a clinical trial. Elucidators should use 
the PRPs’ questions to assess their comprehension, educational 
level, scientific and medical knowledge, and home background, 
and assess why PRPs want such information. Elucidators must 
understand that they cannot always adequately address patients’ 
questions and concerns during the initial recruitment and consent 
process. They must recognise that IC is a process not a onetime 
event. They must continually engage PRPs in discussions of the trial 
design, conduct, and outcomes throughout the research process, 
especially for studies involving cutting-edge interventions.
• Information should be explained using simple words and easily 
understood expressions. In our workshop, those involved in stem 
Table 2. Points of attention for informed consent
• SITUATION: Informed consent should be conducted not in places which conjure images of medical treatment such as a medical 
examination room. Thus, white coats should not be worn to avoid prospective participants’ misunderstanding the process for therapy.
• PERCEPTION: It is important to understand what patients know and expect.
• INFORMATION: Information should be delivered without using scientific jargon and technical terms so that it can be understood by 
prospective participants.
• KNOWLEDGE: Make sure that prospective participants gain enough knowledge throughout the IC process to assess the meaning of 
becoming research participants and what would happen to them while participating in research.
• EMPATHY: Try to understand prospective research participants’ emotion such as fear and hope. Thus, always pay attention to not only 
prospective research participants’ words but also to their body language and attitudes and tones.
• SOLUTION: Regardless of obtaining prospective research participants’ agreement or not, make sure that they understand the next 
procedure after they leave the room, such as making the next appointment for medical treatment or giving them contact address 
and advising them to consult with their family members. Also, people who conduct informed consent need to be aware that they are 
responsible for judging participation eligibility in the research of patients.[6]
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cell research and IC support sometimes found it difficult to 
explain scientific matters without using technical terms. PRPs 
often misunderstand that the purpose of a phase-I clinical trial is 
to evaluate safety, not to find a cure. Elucidators must be able to 
explain research without causing therapeutic misconceptions and 
to ensure PRPs’ comprehension in a limited amount of time.
• Elucidators must build their empathy skills and be able to create 
a rapport that enables PRPs to voice their concerns and ask 
questions, and enables elucidators to recognise the non-verbal 
communication signs expressed by PRPs about the information 
being communicated or other factors that may influence their 
decision-making.
What information do research volunteers want to 
know?
In 2013, the Japanese Retinitis Pigmentosa Society (JRPS) held a 
workshop for regional leaders. After hearing lectures on iPS re-
search, the research process, ethical issues (including therapeutic 
misconceptions), and participants’ rights and duties, the patients and 
their families were divided into eight groups of six members to discuss 
what information they would like when considering participating in a 
clinical trial. Following is a summary of the information that patients 
wanted, identified from their comments in the workshop report.[7]
• Foreseeable risks and problems, including information on adverse 
events:
‘[I] would like to know [if it is] possible [for this cancer to] spread all over the 
body, [and if so, should]...the whole or part [of] the eye...be [removed]?’[7]
• Expected burdens and restrictions in daily life, including economic 
and family burdens:
‘…I would like to know if there is something that [will] restrict my daily life 
during the follow-up period…. First of all, we would like to get better and 
contribute to the research. However, I am wondering if I [have to] abstain 
from alcohol entirely for three years thereafter.’[7]
• Physical, psychological, and economic support, including follow-
up care and insurance when an adverse event occurs: 
‘We would like to know what kind of care would be provided for each 
adverse event. We are informed of possible risks in advance, but we would 
like to know what concrete care [is offered for] each specific adverse 
event. …We would like to know… the care [offered] if someone’s eyesight 
was impaired or [he or she] became blind. … We would [also] like to know 
the medical treatment and/or economic support [offered] for physical 
symptoms or mental aberrations if they happen.’[7]
• Other studies or alternative therapies: One PRP’s concern was 
whether participating in certain research would limit access to 
other studies or therapies, or whether participants could easily 
switch to alternative options if they changed their mind.
‘… we would like to know if other… research [is currently being 
conducted], not limited to iPS cells, but [interventions] such as artificial 
retinas and gene therapy. We would like to know of…[issues such as] 
expected future effects.’[7]
• Previous PRP results and experiences: From a scientific perspective, 
it is preferable not to share results from previous research 
participants. However, based on the dialogue and our experiences, 
patients want such information when they are making their 
decisions.
‘Second is the information about [previous PRPs’ experiences] in the 
clinical trial. We would like to know if and when … previous research 
participants’ results [will be available] …’[7]
• What patients can do to prevent adverse events so that they are 
not disqualified as research participants.
‘… we would like to [know] what we should pay attention to in daily life 
so as not to cause adverse events [that could] prevent us from [continuing 
to] participate in the research.’[7]
Patients also wanted other information, such as: 
• Why they were selected as research participants 
• Expected realistic benefits 
• Schedules, test items, and restrictions 
• Treatments and support, if they developed research-unrelated 
diseases 
• Restrictions related to pregnancy.
Finally, the patients had requests and suggestions on the research on 
retinitis pigmentosa: 
• Suggestions for research designs from a scientific perspective 
• Requests for consultation services provided by a third party 
• Requests for thorough cell-quality management, such as con-
tamination prevention 
• Requests for a mutual-check system of institutional review boards 
involving representatives from patient groups 
• The necessity for educational activities conducted by and for the 
patients themselves. 
Overall, the patients were concerned about how participating would 
impact their daily routines and quality of life, and wanted concrete, 
precise information before making a decision. Well-written consent 
forms usually include much of the information desired by patients, 
although patients often want more informational certainty than can 
be provided. 
Discussion 
Many studies have been conducted on improving consent forms and 
readability as well as assessing PRPs’ comprehension, such as the ISSCR 
guidelines, which propose a written test or an oral quiz during IC.[4] In 
those cases, the focus is on PRPs’ comprehension and scientific literacy. 
However, stem cell research is very technical and, as with much medical 
research, there is information asymmetry between laypeople and 
elucidators, particularly where those elucidators are researchers. Hence, 
relying solely on written consent forms or educating the PRP in initial IC 
is not enough to achieve IC. Results from the IC workshops discussed 
in this paper suggest that improving elucidators’ IC competencies is 
another important and essential element in achieving IC. 
The competencies required for competent elucidators include 
not only an ability to explain the research and enhance PRPs’ 
understanding, but also an ability to judge PRPs’ voluntariness and 
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eligibility to participate in the research. Out of thousands of patients, 
only a few people will be selected to enrol in an iPSC-FIH clinical trial 
and to establish iPSC lines, at a cost of tens of thousands of yen per 
patient.[7] Those selected PRPs carry the hopes of patient groups, 
researchers, and the country, putting them under implicit and explicit 
pressures, especially if they want to withdraw from the trial.[7] Thus, 
securing research participants’ voluntariness and ensuring the right 
to withdraw from the research is a significant role for elucidators.
Sharing research results with participants is also a challenging issue 
for elucidators. Various medical examinations are conducted in the 
process of stem cell research, such as screenings for infectious diseases 
and cancers, whole genome sequencing, among others. If minors are 
included as PRPs, a positive result for a sexually transmitted disease may 
impact the protection of his or her confidentiality as an adolescent, along 
with parental responsibility. Cancer screenings would also be conducted 
prior to a PRP being cleared to participate,[7] and whole genome 
sequencing might be conducted to maintain the quality of cell products 
for allogenic cell therapy. Obviously, these test results could affect a PRP’s 
quality of life. In order to competently deal with such diverse issues, 
elucidators must be able to catch signs of anxiety and concern in PRPs 
during IC, as expressed verbally and non-verbally by the participants. This 
requires astute communication skills, not often learned by researchers.
Elucidators also need an ability to establish and maintain 
partnerships with both PRPs and investigators to ensure long-term 
safety. Monitoring and ensuring the long-term safety of both active 
research participants and those who withdraw from the study is also 
important, due to the essential nature of stem cell research. It may 
not be possible to remove the implanted cells from the body of either 
active or inactive patients. An elucidators’ ability to deal appropriately 
with people in the multiple contexts of stem cell research is another 
crucial element in protecting research volunteers. 
In summary, elucidators need to act not only as information 
providers assisting PRPs with decision-making, but also as gatekeepers 
and coordinators. The complexity of their responsibilities will grow as 
stem cell research advances. Continuous training and education is 
essential for elucidators to acquire and maintain such complex skill 
sets and IC competencies in stem cell research. As demonstrated by 
the workshops, role-playing can be a practical method of transmitting 
such knowledge and IC competency.
Due to the limitations of our study, additional research is required 
to confirm whether there are any traits specific to stem cell research 
in general. Further research is also necessary to confirm what items 
should be included in elucidators’ IC competency.
Conclusion
In our IC workshops, we could not find any specific IC requirements 
for stem cell research. Well-written consent forms cover most of the 
information that research volunteers want to know. However, relying 
only on consent forms is not enough to achieve IC. The IC competency 
of elucidators is another element in protecting research volunteers. 
The elucidator’s role requires skill at explaining the research, 
enhancing PRPs’ understanding, and judging PRPs’ voluntariness 
and eligibility to participate in the research. The need for ongoing 
education and training of elucidators is essential to their acquiring 
and maintaining the skill sets needed for them to fulfil their complex 
role in obtaining full IC for stem cell research. 
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